Beyondspring Inc (NASDAQ:BYSI) Stock Soars: H.C. Wainwright Upgardes With $100 PT

August 4, 2021

Shares of Beyondspring Inc (NASDAQ:BYSI) soared 170% to $26.06 after the company announced positive topline data of DUBLIN-3 trial in plinabulin in combination with docetaxel (DP) to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (D) (n=559). H.C. Wainwright upgrades BYSI to Buy from Neutral and sets target price at $100. Analyst Joseph Pantginis said, “Dublin-3 provides some beautiful summer fireworks with endpoints met, representing…

Read More >>

BeyondSpring (NASDAQ:BYSI) Stock All Set To Gap Up: How to Trade Now?

August 4, 2021

BeyondSpring (NASDAQ:BYSI) is the biggest gainer in the pre-market session after announcing positive topline data of DUBLIN-3 trial in plinabulin in combination with docetaxel (DP) to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (D) (n=559). The combination met the primary endpoint of increasing overall survival (OS) (mean OS, p=0.03; OS log rank: p <0.04). The study also met key secondary endpoints, including significantly improving…

Read More >>